These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39317891)

  • 1. Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial.
    Yılmaz F; Yaşar S; Mandel NM; Kaçan T; Özdemir M; Doğu GG; Şengül N; Meydan N; Başal FB; Tolunay PK; Hamamcı MB; Dinçer OS; Bahçeci A; Özer L; Ajredini M; Kırca Ö; Yersal Ö; Can O; Günaldı M; Demir G; Yalçın Ş
    Target Oncol; 2024 Sep; ():. PubMed ID: 39317891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
    Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
    Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
    Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.
    Zhou KI; Vashistha V; Guo A; Ahmed S; Kelley MJ
    JCO Precis Oncol; 2023 Mar; 7():e2200692. PubMed ID: 36926986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
    Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Demetri GD; De Braud F; Drilon A; Siena S; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Lin JJ; Goto K; Lee J; Bazhenova L; John T; Fakih M; Chawla SP; Dziadziuszko R; Seto T; Heinzmann S; Pitcher B; Chen D; Wilson TR; Rolfo C
    Clin Cancer Res; 2022 Apr; 28(7):1302-1312. PubMed ID: 35144967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
    Wu WC; Chen MH
    Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
    Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
    PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan.
    Nakata E; Osone T; Ogawa T; Taguchi T; Hattori K; Kohsaka S
    Cancer Med; 2024 Jun; 13(12):e7351. PubMed ID: 38925616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series.
    Yokota T; Yukino H; Doi M; Ohori H
    Head Neck; 2023 May; 45(5):E10-E15. PubMed ID: 36924196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer.
    Koehler VF; Achterfeld J; Sandner N; Koch C; Wiegmann JP; Ivanyi P; Käsmann L; Pusch R; Wolf D; Chirica M; Knösel T; Demes MC; Kumbrink J; Vogl TJ; Meyer G; Spitzweg C; Bojunga J; Kroiss M
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14035-14043. PubMed ID: 37548775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
    Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE
    Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases.
    Metellus P; Camilla C; Bialecki E; Beaufils N; Vellutini C; Pellegrino E; Tomasini P; Ahluwalia MS; Mansouri A; Nanni I; Ouafik L
    Front Oncol; 2024; 14():1382394. PubMed ID: 39087020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
    Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.